ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Channel Therapeutics Corporation

Channel Therapeutics Corporation (CHRO)

1.16
-0.04
( -3.33% )

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
1.16
Bid
-
Offer
-
Volume
13,390
1.1485 Day's Range 1.20
0.45 52 Week Range 3.80
Market Cap
Previous Close
1.20
Open
1.20
Last Trade
20
@
1.18
Last Trade Time
05:54:45
Financial Volume
US$ 15,623
VWAP
1.1668
Average Volume (3m)
765,777
Shares Outstanding
6,595,850
Dividend Yield
-
PE Ratio
-0.96
Earnings Per Share (EPS)
-1.21
Revenue
-
Net Profit
-7.96M

About Channel Therapeutics Corporation

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. I... Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Reno, Nevada, USA
Founded
-
Channel Therapeutics Corporation is listed in the Biological Pds,ex Diagnstics sector of the American Stock Exchange with ticker CHRO. The last closing price for Channel Therapeutics was US$1.20. Over the last year, Channel Therapeutics shares have traded in a share price range of US$ 0.45 to US$ 3.80.

Channel Therapeutics currently has 6,595,850 shares in issue. The market capitalisation of Channel Therapeutics is US$7.92 million. Channel Therapeutics has a price to earnings ratio (PE ratio) of -0.96.

CHRO Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.18-13.43283582091.341.361.16305761.22542965CS
40.229324.63736972170.93071.38990.9499481.18989008CS
12-0.79-40.51282051281.952.370.97657771.78197689CS
260.51479.56656346750.6463.80.5627869862.09019844CS
52-0.25-17.73049645391.413.80.454330771.9401349CS
156-4.84-80.6666666667660.453288121.95406023CS
260-4.84-80.6666666667660.453288121.95406023CS

CHRO - Frequently Asked Questions (FAQ)

What is the current Channel Therapeutics share price?
The current share price of Channel Therapeutics is US$ 1.16
How many Channel Therapeutics shares are in issue?
Channel Therapeutics has 6,595,850 shares in issue
What is the market cap of Channel Therapeutics?
The market capitalisation of Channel Therapeutics is USD 7.92M
What is the 1 year trading range for Channel Therapeutics share price?
Channel Therapeutics has traded in the range of US$ 0.45 to US$ 3.80 during the past year
What is the PE ratio of Channel Therapeutics?
The price to earnings ratio of Channel Therapeutics is -0.96
What is the reporting currency for Channel Therapeutics?
Channel Therapeutics reports financial results in USD
What is the latest annual profit for Channel Therapeutics?
The latest annual profit of Channel Therapeutics is USD -7.96M
What is the registered address of Channel Therapeutics?
The registered address for Channel Therapeutics is 50 WEST LIBERTY STREET, SUITE 880, RENO, NEVADA, 89501
What is the Channel Therapeutics website address?
The website address for Channel Therapeutics is channeltherapeutics.com
Which industry sector does Channel Therapeutics operate in?
Channel Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAPXT Rex 2X Long Apple Daily Target ETF
US$ 0.00
(0.00%)
0
AAPWRoundhill AAPL WeeklyPay ETF
US$ 0.00
(0.00%)
0
AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026
US$ 0.00
(0.00%)
0
AAAUGoldman Sachs Physical Gold ETF Shares
US$ 0.00
(0.00%)
0
AAAAlternative Access First Priority CLO Bond ETF
US$ 0.00
(0.00%)
0
AAPXT Rex 2X Long Apple Daily Target ETF
US$ 0.00
(0.00%)
0
AAPWRoundhill AAPL WeeklyPay ETF
US$ 0.00
(0.00%)
0
AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026
US$ 0.00
(0.00%)
0
AAAUGoldman Sachs Physical Gold ETF Shares
US$ 0.00
(0.00%)
0
AAAAlternative Access First Priority CLO Bond ETF
US$ 0.00
(0.00%)
0
AAPXT Rex 2X Long Apple Daily Target ETF
US$ 0.00
(0.00%)
0
AAPWRoundhill AAPL WeeklyPay ETF
US$ 0.00
(0.00%)
0
AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026
US$ 0.00
(0.00%)
0
AAAUGoldman Sachs Physical Gold ETF Shares
US$ 0.00
(0.00%)
0
AAAAlternative Access First Priority CLO Bond ETF
US$ 0.00
(0.00%)
0

CHRO Discussion

View Posts
Monksdream Monksdream 2 months ago
CHRO,under $2
👍️0
makinezmoney makinezmoney 2 months ago
$CHRO: Merging with Ligands' Pelthos..........


https://finance.yahoo.com/news/ligand-subsidiary-pelthos-therapeutics-combine-100000828.html

Channel Therapeutics Corporation - $CHRO - 🇺🇸

Sector: Healthcare - Biotechnology
Market Cap: 7.66M
Float: 1.24M

News: Ligand Pharmaceuticals’ subsidiary, Pelthos Therapeutics, will merge with Channel Therapeutics in a $50M equity deal to form Pelthos Therapeutics Inc., trading on NYSE American as PTHS. Ligand will invest $18M, retaining a 13% royalty on ZELSUVMI™, an FDA-approved topical gel for molluscum contagiosum, the first at-home prescription therapy. Led by Pelthos CEO Scott Plesha and Channel’s CFO Frank Knuettel, the company will commercialize ZELSUVMI and advance Channel’s NaV 1.7 non-opioid pain treatments. The $32M deal, backed by a Murchinson-led group, will close in summer 2025. Molluscum contagiosum, a contagious skin infection, affects 16.7M in the U.S.

GO $CHRO
👍️0
makinezmoney makinezmoney 2 months ago
$CHRO: BOooommmmmmm........... Bagger now $2.10

There it goes........... Mega POP.

Only $1.25 yesterday and there she goes.


GO $CHRO
👍️0
glenn1919 glenn1919 4 months ago
CHRO.........................https://stockcharts.com/h-sc/ui?s=CHRO&p=W&b=5&g=0&id=p86431144783
👍️0
Invest-in-America Invest-in-America 5 months ago
CHRO: Whelp, looks like we can all thank iHub's Colonel GLENN, on THAT note now, Homeboy.
👍️0
tw0122 tw0122 5 months ago
$3.08 + 60% Meant to tell you a Friday when still in $1s to
Open board but you got it done 
👍️0
Invest-in-America Invest-in-America 5 months ago
CHRO: Micro-FLoat, NO-BRAINER!!
👍️0
Invest-in-America Invest-in-America 5 months ago
CHRO: WOW!!
👍️0
glenn1919 glenn1919 5 months ago
CHRO............................https://stockcharts.com/h-sc/ui?s=CHRO&p=W&b=5&g=0&id=p86431144783
👍️0

Your Recent History

Delayed Upgrade Clock